Biostatistician | Clinical Trial Designer | Founder of Evidence in the Wild & Zetyra

I build statistical design tools and provide consulting services for clinical trials, specializing in oncology and adaptive designs.

I spent nearly a decade as a biostatistician at Fred Hutchinson Cancer Center and SWOG, specializing in oncology trial design and Phase II adaptive designs.

During that time, I identified recurring failure patterns: protocols locked in before anyone stress-tested the assumptions, interim decisions made on gut instead of simulation, sample sizes calculated once and never revisited. I call these "Zombie Trials"—studies continuing enrollment after mathematical evidence suggested stopping.

I founded Evidence in the Wild and Zetyra on the belief that the most expensive experiment is the one that was doomed from the start.

What drives my work:

• Building Zetyra: the tool I wished I had, combining rigorous validated methods with a modern interface that doesn't require a PhD to operate
• Providing honest consulting through Evidence in the Wild on trial design before teams invest millions
• Democratizing statistical tools traditionally locked behind $5,000-$15,000/year enterprise paywalls

Beyond work, I train for Ironman and marathon competitions. Pacing matters in both athletics and trial design.

Core Philosophy:

• Web-First: Browser-based, shareable designs without installation barriers
• Collaborative: Project-based workflow with scenario comparison and professional reporting
• Transparent: Visible methodology using industry-standard, peer-reviewed packages (gsDesign, SciPy)

Evidence in the Wild provides specialized consulting services for clinical trial statistical design.

Protocol Statistical Review

• Evaluate draft protocols to identify design flaws before expensive development phases
• Review sample size assumptions, endpoint selection, and interim analysis strategies
• Typical turnaround: 1-2 weeks

Sample Size & Power Consultation

• Justified sample sizing for grants, protocols, and regulatory submissions
• Covariate adjustment strategies (CUPED, ANCOVA)
• Adaptive design feasibility assessment
• Simulation-based operating characteristics

Adaptive Design Feasibility

• Honest assessment of whether adaptive designs warrant operational complexity
• Statistical efficiency tradeoff analysis
• Implementation roadmap for complex designs

Interim Analysis & Futility Planning

• Design interim looks and stopping rules before trial launch
• Bayesian predictive power calculations
• Alpha spending frameworks (O'Brien-Fleming, Pocock)
• Futility boundary design

• Early-stage biotech (Series A/B) needing statistical design expertise
• Academic investigators pursuing R01 grants or cooperative group proposals
• CROs requiring independent statistical review
• Medical device companies building biometrics infrastructure

I focus on high-level trial design. I don't provide hourly SAS programming, data cleaning services, or tutoring.

→ Learn more about consulting services

Zetyra is a web-based statistical software platform democratizing efficient clinical trial design.

Phase III oncology trials average $50-100M and take 4-6 years to complete. Conservative design practices inflate costs by ignoring baseline correlations, using fixed-sample designs without interim monitoring, and applying frequentist methods for early-stage decisions. Traditional tools (PASS, nQuery) cost $5,000-$15,000/year per seat with no validation transparency.

Core Methodologies:

• CUPED - 15-35% sample size reduction using baseline-outcome correlations (FDA-endorsed)

• Group Sequential Design - 15-40% expected sample size reduction with interim monitoring (validated against gsDesign R package)

• Bayesian Predictive Power - Quantitative go/no-go decisions using interim data (aligns with FDA draft guidance)

Features: Free tier with all calculators, project management, PDF export, 51 automated tests, transparent validation

→ Try Zetyra | Read the Whitepaper

Building tools and providing expertise to make rigorous statistical design accessible to everyone running clinical trials.